MEPs believe that pharmaceutical-related TRIPS affecting public health and access to medicines which go beyond the TRIPS Agreement should be excluded from EPAs and other future bilateral or regional agreements with low-income countries.
Ziņojums: Specifiskas problēmas to tiesību aktu transponēšanā un īstenošanā, kuri attiecas uz valsts iepirkumu, un to saistība ar Lisabonas programmu